SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
President Donald Trump listens as Dr. Moncef Slaoui, the former head of GlaxoSmithKlines vaccines division, speaks about coronavirus vaccine development in the Rose Garden of the White House on May 15, 2020. (Photo: Drew Angerer/Getty Images)
Trump's Vaccine Chief Picks His Own Former Employer--Where He Still Holds Millions Worth of Stock--for $2.1 Billion Deal
"You can't have a contractor supervising government officials."
Jul 31, 2020
The White House on Friday awarded a record-breaking $2.1 billion contract for development of a Covid-19 vaccine, raising questions about a former pharmaceutical executive's involvement in the administration's decision.
The deal is for 100 million doses of a vaccine manufactured by Sanofi, a French drug maker, and its British partner GlaxoSmithKline (GSK).
As Fortune reported:
The deal follows billions of dollars of U.S. commitments to other experimental vaccines--all still needing to show their effectiveness in testing--and may stoke concerns that other countries will be left behind. Vaccines are seen as the key to leading the world out of the pandemic that has killed about 675,000 people in a matter of months.
Dr. Moncef Slaoui, a former GSK executive, is head of the White House's Operation Warp Speed, the administration's program to develop and disburse an effective coronavirus vaccine. Slaoui's connection to his former company has been the focus of concern from advocacy groups and politicians skeptical of his claims of neutrality.
According to the New York Times:
Dr. Slaoui is not a federal employee, instead working under a $1 contract that exempts him from federal rules that would require him to list his outside positions, stock holdings and other potential conflicts. Dr. Slaoui said in an interview in May that he was determined to avoid any conflicts of interest, but that his GSK stock represented his retirement from 29 years at the company, and that he had told federal officials he would not take the job if he had to sell it.
Sen. Elizabeth Warren (D-Mass.) raised concerns over Slaoui's ties to GSK in May.
"It is a huge conflict of interest for the White House's new vaccine czar to own $10 million of stock in a company receiving government funding to develop a Covid-19 vaccine," Warren tweeted. "Dr. Slaoui should divest immediately."
As Common Dreams reported, the former executive's refusal to relinquish his shares in the company made the process of awarding a contract a "sham," in the words of former Office of Government Ethics director Walter Shaub.
"You can't have a contractor supervising government officials," said Shaub.
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, The U.S. is on a fast track to authoritarianism like nothing I've ever seen. Meanwhile, corporate news outlets are utterly capitulating to Trump, twisting their coverage to avoid drawing his ire while lining up to stuff cash in his pockets. That's why I believe that Common Dreams is doing the best and most consequential reporting that we've ever done. Our small but mighty team is a progressive reporting powerhouse, covering the news every day that the corporate media never will. Our mission has always been simple: To inform. To inspire. And to ignite change for the common good. Now here's the key piece that I want all our readers to understand: None of this would be possible without your financial support. That's not just some fundraising cliche. It's the absolute and literal truth. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. Will you donate now to help power the nonprofit, independent reporting of Common Dreams? Thank you for being a vital member of our community. Together, we can keep independent journalism alive when it’s needed most. - Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
The White House on Friday awarded a record-breaking $2.1 billion contract for development of a Covid-19 vaccine, raising questions about a former pharmaceutical executive's involvement in the administration's decision.
The deal is for 100 million doses of a vaccine manufactured by Sanofi, a French drug maker, and its British partner GlaxoSmithKline (GSK).
As Fortune reported:
The deal follows billions of dollars of U.S. commitments to other experimental vaccines--all still needing to show their effectiveness in testing--and may stoke concerns that other countries will be left behind. Vaccines are seen as the key to leading the world out of the pandemic that has killed about 675,000 people in a matter of months.
Dr. Moncef Slaoui, a former GSK executive, is head of the White House's Operation Warp Speed, the administration's program to develop and disburse an effective coronavirus vaccine. Slaoui's connection to his former company has been the focus of concern from advocacy groups and politicians skeptical of his claims of neutrality.
According to the New York Times:
Dr. Slaoui is not a federal employee, instead working under a $1 contract that exempts him from federal rules that would require him to list his outside positions, stock holdings and other potential conflicts. Dr. Slaoui said in an interview in May that he was determined to avoid any conflicts of interest, but that his GSK stock represented his retirement from 29 years at the company, and that he had told federal officials he would not take the job if he had to sell it.
Sen. Elizabeth Warren (D-Mass.) raised concerns over Slaoui's ties to GSK in May.
"It is a huge conflict of interest for the White House's new vaccine czar to own $10 million of stock in a company receiving government funding to develop a Covid-19 vaccine," Warren tweeted. "Dr. Slaoui should divest immediately."
As Common Dreams reported, the former executive's refusal to relinquish his shares in the company made the process of awarding a contract a "sham," in the words of former Office of Government Ethics director Walter Shaub.
"You can't have a contractor supervising government officials," said Shaub.
The White House on Friday awarded a record-breaking $2.1 billion contract for development of a Covid-19 vaccine, raising questions about a former pharmaceutical executive's involvement in the administration's decision.
The deal is for 100 million doses of a vaccine manufactured by Sanofi, a French drug maker, and its British partner GlaxoSmithKline (GSK).
As Fortune reported:
The deal follows billions of dollars of U.S. commitments to other experimental vaccines--all still needing to show their effectiveness in testing--and may stoke concerns that other countries will be left behind. Vaccines are seen as the key to leading the world out of the pandemic that has killed about 675,000 people in a matter of months.
Dr. Moncef Slaoui, a former GSK executive, is head of the White House's Operation Warp Speed, the administration's program to develop and disburse an effective coronavirus vaccine. Slaoui's connection to his former company has been the focus of concern from advocacy groups and politicians skeptical of his claims of neutrality.
According to the New York Times:
Dr. Slaoui is not a federal employee, instead working under a $1 contract that exempts him from federal rules that would require him to list his outside positions, stock holdings and other potential conflicts. Dr. Slaoui said in an interview in May that he was determined to avoid any conflicts of interest, but that his GSK stock represented his retirement from 29 years at the company, and that he had told federal officials he would not take the job if he had to sell it.
Sen. Elizabeth Warren (D-Mass.) raised concerns over Slaoui's ties to GSK in May.
"It is a huge conflict of interest for the White House's new vaccine czar to own $10 million of stock in a company receiving government funding to develop a Covid-19 vaccine," Warren tweeted. "Dr. Slaoui should divest immediately."
As Common Dreams reported, the former executive's refusal to relinquish his shares in the company made the process of awarding a contract a "sham," in the words of former Office of Government Ethics director Walter Shaub.
"You can't have a contractor supervising government officials," said Shaub.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.